肿瘤免疫与T细胞识别青年研究组

  获奖情况

2017年  获第七届中国免疫学会青年学者奖

1.Li, Z.#, Li, S#, Zhang G#, Peng W#, Chang Z, Zhang X, Fan Z, Chai Y, Wang F, Zhao X, Li D, Zhang R, He Z, Xu K, Lei W, Liu P, Hao J, Zhang J, Sun L, Wu G,Tan S*, Gao GF*, Gao F*, Wu Y*. An engineered bispecific human monoclonal antibody against SARS-CoV-2.Nature Immunology.2022 Mar;23(3):423-430

2.Sun M, Zhang H, Chai Y, Jiang M, Qi J, Gao G.F.*,Tan S*.Structural insights into the cis and trans assembly of human trophoblast cell surface antigen 2.iScience.2021. Sep 30;24(10):103190.

3.Zhao M#, Fu L#, Chai Y, Sun M, Li Y, Wang S, Qi J, Zeng B, Kang L, Gao G.F.*,Tan S*.Atypical TNF-TNFR superfamily binding interface in GITR-GITRL complex for T cell activation.Cell Reports2021. 36, 109734.

4.Zhang H, Sun M, Wang J, Zeng B, Cao X, Han Y,Tan S*and Gao GF*.Identificationof NY-ESO-1_157-165specific murine T cell receptors with distinct recognition patterns for tumor immunotherapy.Frontiers in Immunology.2021. Mar 23;12:644520.

5.Liu K#,Tan S#,Niu S#, Wang J#,Wu L, Sun H, Zhang Y, Pan X, Qu X, Du P, Meng Y, Jia Y, Chen Q, Deng C, Yan J, Wang H, Wang Q*, Qi J*, Gao GF*. Cross-species recognition of SARS-CoV-2 to bat ACE2.Proceedings of the National Academy of Sciences of the United States of America. 2021 Jan 5;118(1):e2020216118.

6.Liu H#, Bi X #, Zhang J, Zhou Y, Shi R, Chai Y, Li B, Liu D, Liu H, Yao J, Wu H, Yao S, Qi J, Feng H, Feng M*, Yan J *,Tan S *. Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy.Signal Transduction and Targeted Therapy.5, 158 (2020).

7.Liu K#,Tan S#*, Jin W, Guan J, Wang Q, Sun H, Qi J, Yan J, Chai Y, Wang Z, Deng C*, Gao G.F.*. N-glycosylation of PD-1 promotes binding of camrelizumab.EMBO Reports.2020, e51444.

8.Liu K#, Meng Y#, Chai Y, Li L, Sun H, Gao GF,Tan S*, Qi J*, Crystal structure of the African swine fever virus core shell protein p15.Biosafety and Health.2020, doi.org/10.1016/j.bsheal.2020.09.002.

9.Chen D#,Tan S#, Zhang H#, Wang H#, He W, Shi R, Tong Z, Zhu J, Cheng H, Gao S, Chai Y, Qi J, Xiao M, Yan J*, Gao GF*. The FG Loop of PD-1 Serves as a ‘Hot-Spot’ for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy.iScience2019 Apr 26;14:113-124.

10.Liu H,#, Guo L #, Zhang J, Zhou Y, Zhou J, Yao J, Wu H, Yao S, Chen B, Chai Y, Qi J, Gao GF,Tan S*, Feng H*, Yan J*. Glycosylation independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy.mAbs.2019.May/Jun;11(4):681-690

11.Bi Y#,Tan S#,Yang Y#,Wong G#, Zhao M, Zhang Q, Wang Q, Zhao X, Li L, Yuan J, Li H, Li H, Xu W, Shi W, Quan C, Zou R, Li J, Zheng H, Yang L, Liu WJ, Liu D, Wang H, Qin Y, Liu L, Jiang C, Liu W, Lu L, Gao GF*, Liu Y*.. Clinical and immunological characteristics of human infections with H5N6 avian influenza virus.Clinical Infectious Diseases. 2019. 68(7):1100–9

12.Wang H, Qi J, Zhang S, Li Y,Tan S*& Gao GF*. Binding mode of the side-by-side two-IgV molecule CD226/DNAM-1 to its ligand CD155/Necl-5.Proceedings of the National Academy of Sciences of the United States of America.2019. Jan 15;116(3):988-996.

13.Li Y#,Tan S#,Zhang C#, Chai Y, He M, Zhang C. W., Wang Q, Tong Z, Liu K, Lei Y, Liu W, Liu Y, Tian Z, Cao X, Yan J, Qi, J, Tien P*, Gao S*, Gao GF*. Limited cross-linking of 4-1BB by 4-1BB ligand and the agonist monoclonal antibody utomilumab.Cell Reports. 2018.25(4):909-920.e4.

14.Zhao M#, Chen J#,Tan S#, Dong T, Jiang H, Zheng J, Quan C, Liao Q, Zhang H, Wang X, Wang Q, Bi Y, Liu F, Feng L, Horby PW, Klenerman P, Gao GF, Liu WJ*, Yu H*. Prolonged evolution of virus-specific memory T cell immunity post severe avian influenza A (H7N9) virus infection.Journal of Virology.2018 Jun 20. pii: JVI.01024-18.

15.Tan S#, Liu K#, Chai Y, Zhang C. W.-H. Gao S, Gao G.F., Qi J. Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab.Protein &Cell.2018 Jan; 9(1): 135–139.

16.谭曙光，高福.精准医疗与肿瘤免疫治疗伴随诊断.生物产业技术. 2018. 02（3月）.

17.谭曙光,施一,刘军,高福.艾滋病疫苗突破需要颠覆性思维.科学通报.2018. 63, 9

18.Tan S#,Zhang H#, Chai Y#, Song H, Tong Z, Wang Q, Qi J, Wong G, Zhu X, Liu WJ, Gao S, Wang Z, Shi Y,  Yang F, Gao GF, Yan J. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.Nature Communications．2017 Feb 6;8:14369.

19.Liu K#,Tan S#, Chai Y, Chen D, Song H, Zhang CW, Shi Y, Liu J, Tan W, Lyu J, Gao S, Yan J, Qi J*, Gao GF*. Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy.Cell Research.2017 Jan;27(1):151-153.

20.Tan S#, Zhang S#, Wu B#, Zhao Y, Zhang W, Han M, Wu Y, Shi G, Liu Y, Yan J, Wu G, Wang H, Gao GF, Zhu F, Liu WJ. Hemagglutinin-specific CD4+ T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans. Vaccine. 2017.Oct 9;35(42):5644-5652.

21.Tan S, Lin N, Huang M, Wang Q, Tan Y, Li B, Zhang N, Guo T, Cui Y, Chen X, Wang D, Wang J, Xiao H, Liu W.J., Yan J, Zhang C.W., Liu C, Wan K, Gao GF. CTL immunogenicity of Rv3615c antigen and diagnostic performances of an ESAT-6/CFP-10/Rv3615c antigen cocktail for Mycobacterium tuberculosis infection.Tuberculosis. 2017. Dec;107:5-12

22.He M#, Chai Y#, Qi J, Zhang C. W.-H., Tong Z, Shi Y, Yan J,Tan S*and Gao G.F.* Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelizumab antibodies.Oncotarget.2017; 8:67129-67139.

23.Liu WJ #, Sun Y#, Shi W#,Tan S#, Pan Y, Cui S, Zhang Q, Dou X, Lv Y, Li X, Li X, Chen L, Quan C, Wang Q, Zhao Y, Lv Q, Hua W, Zeng H, Chen Z, Xiong H, Jiang C, Pang X, Zhang F, Liang M, Wu G, Gao GF, Liu WJ*, Li A*, Wang Q*. The first imported case of Rift Valley fever in China reveals a genetic reassortment of different viral lineages.Emerging Microbes and Infection.2017.Jan 18;6(1):e4.

24.Tan S,Chen D, Liu K, He M, Song H, Shi Y, Liu J, Zhang C. W.-H., Qi J, Yan J, Gao S*, Gao G.F.* Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies.Protein &Cell.2016 Dec;7(12):866-877

25.Tan S,Zhang C. W-H., Gao GF*. Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy.Signal Transduction and Targeted Therapy.2016 Nov 25;1:16029.

26.Liu WJ#,Tan S#,Zhao M#, Quan C, Bi Y, Wu Y, Zhang S, g H, Xiao H, Qi J, Yan J, LiuW, Yu H, Shu Y, Wu G, Gao GF*. Cross-immunity Against Avian Influenza A(H7N9) Virus in the Healthy Population Is Affected by Antigenicity-Dependent Substitutions.Journal of Infectious Diseases.2016. Dec 15;214(12):1937-1946.

27.谭曙光，高福。肿瘤治疗的新希望：免疫疗法.科学通报. 2015，11，60-3155-3157.

28.Tan S, Tan X, Liu J, Sun X , Lu G, Chen C, Yan J, Xu W*, Gao GF*. VP2 dominated CD4+ T cell responses against enterovirus 71 and cross-reactivity against coxsackievirus A16 and polioviruses in a healthy population.Journal of Immunology.2013 Aug 15;191(4):1637-47.

29.Liu J#, Zhang S#,Tan S#, Yi Y, Wu B, Cao B, Zhu F, Wang C, Wang H, Qi J, Gao GF*. Cross-allele cytotoxic T lymphocyte responses against 2009 pandemic H1N1 influenza A virus among HLA-A24 and HLA-A3 supertype-positive individuals.Journal of Virology.2012 Dec;86(24):13281-94.